fasting while on glp 1 aon study Added Value to GLP-1 Receptor Agonist: Intermittent and Lifestyle Modification to Improve Therapeutic Effects and Outcomes Why fasting isn’t recommended with

(2) intervention (exposure) and comparator: SGLT2 inhibitor or GLP-1 receptor agonist monotherapy versus placebo or metformin as a first-line drug

in Spain, its current prevalence ranges between 2833%11,12 and it is a recognized as a cardiovascular risk factor and increases the mortality in this population.1315 Furthermore, in patients with DM2 and advanced CKD there are limitations in the prescription of certain antihyperglycemic drugs (e.g., metformin or sulfonylureas) and there is an increased risk of hypoglycemia with antihyperglycemic treatment,16 a complication that is associated with increased cardiovascular risk17 and hinders the achievement of glycemic control targets

EZ layer formation also leads to the generation of free protons (as hydroxonium ions, and less frequently, solvated hydroxide ions), both of which in the presence of transition metal ions such as Fe(II)/Fe(III), are known to provide catalytic environments for H 2 O 2 redox chemistry [Web ref

If hormonal bloating is part of your picture, digestive sluggishness can slow the excretion of conjugated hormones through the gut